Biohaven

Biohaven CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Biohaven (BHVN) as of Nov 3, 2026 is -0.12 %. In the previous year, CapEx to Operating Cash Flow Ratio was -0.70 % — a change of -83.12% (higher).

CapEx/OCF

-0.12 %

YoY

-83.12%

Last updated:

CapEx to Operating Cash Flow Ratio of Biohaven is 2025 -0.12 % . CapEx to Operating Cash Flow Ratio of Biohaven was 2024 -0.70 % . It decreases by -83.12% higher compared to the previous year.

The Biohaven CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
-2.11 USD
Jan 1, 2019
-0.67 USD
Jan 1, 2020
-3.55 USD
Jan 1, 2021
-0.64 USD
Jan 1, 2022
-13.80 USD
Jan 1, 2023
-0.92 USD
Jan 1, 2024
-0.70 USD
Jan 1, 2025
-0.12 USD
The Biohaven CapEx/OCF history
YEARCapEx/OCFYoY
-0.12 %-83.12%
-0.70 %-24.34%
-0.92 %-93.34%
-13.80 %+2,045.25%
-0.64 %-81.89%
-3.55 %+428.72%
-0.67 %-68.21%
-2.11 %+270.27%
-0.57 %+461.08%
-0.10 %—
0.00-100.00%
-0.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biohaven Stock analysis

What does Biohaven do? Biohaven Pharmaceutical Holding Co. Ltd. generates revenue through the research and development of late-stage product candidates targeting neurological diseases and rare disorders. The company utilizes its glutamate platform to advance clinical-stage compounds for various indications, including trigriluzole for obsessive-compulsive disorder, spinocerebellar ataxia, and Alzheimer's disease. Additionally, the firm develops BHV-0223 for amyotrophic lateral sclerosis and BHV-5000 for conditions such as Rett syndrome, neuropathic pain, and treatment-resistant depression. The business model focuses on identifying and developing clinical-stage compounds that target orphan neurologic indications and other neurological pathways, with the company currently employing 825 full-time employees in New Haven, Connecticut. Biohaven is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biohaven stock

CapEx to Operating Cash Flow Ratio of Biohaven is -0.12 % in 2025.

CapEx to Operating Cash Flow Ratio of Biohaven changed from -0.70 % to -0.12 %, representing a -83.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Biohaven since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Biohaven with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biohaven

All Key Metrics — Biohaven